Filing Flows › Comparisons › CTKB vs PACB
Cytek Biosciences vs Pacific Biosciences of California: CTKB and PACB compared
Cytek Biosciences is the larger company: $53.2M of revenue in its latest quarter (Q3 2026) against $40.6M for Pacific Biosciences of California (Q3 2026). Pacific Biosciences of California is growing faster (+6% against +2% a year earlier). Cytek Biosciences is more profitable, with an operating margin of -15.8% against -91.2%.
Where the money goes: CTKB and PACB
Cytek Biosciences (CTKB) · Q3 2026
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Pacific Biosciences of California (PACB) · Q3 2026
Pacific Biosciences of California, Q3 2026: revenue $40.6M (+6% year over year), operating margin -91.2%, net loss $37.8M, operating cash flow −$37.6M. The chart follows the revenue to costs, profit and cash.
| Cytek Biosciences (CTKB) | Pacific Biosciences of California (PACB) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $53.2M | $40.6M |
| Revenue growth, Y/Y | +2% | +6% |
| Operating margin | -15.8% | -91.2% |
| Net earnings | −$6.1M | −$37.8M |
| Net margin | -11.5% | -93.3% |
| Operating cash flow | −$4.5M | −$37.6M |
Where the revenue comes from
Cytek Biosciences
- Product: $37.2M (70%)
- Service: $16.1M (30%)
Pacific Biosciences of California
- Product revenue: $34.0M (84%)
- Service and other revenue: $6.6M (16%)
Questions
Which is bigger, Cytek Biosciences or Pacific Biosciences of California?
Cytek Biosciences is the larger company: $53.2M of revenue in its latest quarter (Q3 2026) against $40.6M for Pacific Biosciences of California (Q3 2026).
Is Cytek Biosciences or Pacific Biosciences of California growing faster?
Pacific Biosciences of California is growing faster (+6% against +2% a year earlier).
Which is more profitable, Cytek Biosciences or Pacific Biosciences of California?
Cytek Biosciences is more profitable, with an operating margin of -15.8% against -91.2%.
More: Cytek Biosciences earnings · how Cytek Biosciences makes money · Pacific Biosciences of California earnings · how Pacific Biosciences of California makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.